Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Novartis has licensed the tuberculosis-fighting drugs in its portfolio to the nonprofit Global Alliance for TB Drug Development. The drugs, discovered at the Novartis Institutes for Tropical Diseases, include a class of compounds called indolcarboxamides. One of these compounds, NITD304, has been shown to block MmpL3, a protein essential to the TB bacterium’s survival. The agreement calls for the TB Alliance to fully take over Novartis’s TB R&D program, including financial responsibility for approval and distribution of compounds.
This article has been sent to the following recipient: